We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+21.57%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$734M
AUM Growth
+$11.9M
(+1.7%)
Cap. Flow
-$87.4M
Cap. Flow
% of AUM
-11.9%
Top 10 Holdings %
Top 10 Hldgs %
32.05%
Holding
98
New
33
Increased
14
Reduced
20
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$24.8M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$20.6M |
| 3 |
Sanofi
SNY
|
+$19.6M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$19M |
| 5 |
Teleflex
TFX
|
+$15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$34.4M |
| 2 |
McKesson
MCK
|
+$21.7M |
| 3 |
Cytokinetics
CYTK
|
+$21.7M |
| 4 |
Amgen
AMGN
|
+$17.5M |
| 5 |
Cigna
CI
|
+$17.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.31% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Relay Therapeutics
RLAY
$4.38B
| $6.61M | 0.9% |
600,000
-200,000
| -25% | -$1.69M |
|
|
NARI
52
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.49M | 0.88% |
100,000
-250,000
| -71% | -$15.1M |
|
53
Regenxbio
RGNX
$703M
| $5.83M | 0.79% |
+325,000
| New | +$5.72M |
|
54
Revolution Medicines
RVMD
$44.1B
| $5.74M | 0.78% |
200,000
-325,000
| -62% | -$7.81M |
|
|
LBPH
55
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $5.43M | 0.74% |
900,000
+140,000
| +18% | +$698K |
|
56
Avantor
AVTR
$9.31B
| $4.57M | 0.62% |
200,000
-325,000
| -62% | -$6.66M |
|
|
SAGE
57
DELISTED
Sage Therapeutics
SAGE
| $4.33M | 0.59% |
+200,000
| New | +$3.96M |
|
58
MacroGenics
MGNX
$249M
| $4.33M | 0.59% |
+450,000
| New | +$3.11M |
|
59
Agilon Health
AGL
$1.45B
| $4.08M | 0.56% |
+13,000
| New | +$4.7M |
|
60
Acadia Pharmaceuticals
ACAD
$5.07B
| $4.07M | 0.55% |
+130,000
| New | +$3.1M |
|
|
RVNC
61
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.96M | 0.54% |
450,000
+350,000
| +350% | +$2.87M |
|
62
Zentalis Pharmaceuticals
ZNTL
$295M
| $3.79M | 0.52% |
250,000
-200,000
| -44% | -$2.92M |
|
63
Fate Therapeutics
FATE
$319M
| $3.37M | 0.46% |
+900,000
| New | +$2.12M |
|
|
PDCO
64
DELISTED
Patterson Companies, Inc.
PDCO
| $2.85M | 0.39% |
+100,000
| New | +$2.94M |
|
65
Organon & Co
OGN
$3.58B
| $2.16M | 0.29% |
+150,000
| New | +$2.04M |
|
66
Teladoc Health
TDOC
$1.24B
| $2.15M | 0.29% |
100,000
-500,000
| -83% | -$9.22M |
|
67
Tarsus Pharmaceuticals
TARS
$3.05B
| $2.02M | 0.28% |
+100,000
| New | +$1.67M |
|
68
Scholar Rock
SRRK
$6.34B
| $1.88M | 0.26% |
+100,000
| New | +$1.24M |
|
|
VTYX
69
DELISTED
Ventyx Biosciences
VTYX
| $1.24M | 0.17% |
500,000
+70,000
| +16% | +$665K |
|
|
AKRO
70
DELISTED
Akero Therapeutics
AKRO
| – | – |
-100,000
| Closed | -$5.06M |
|
|
71
Amgen
AMGN
$224B
| – | – |
-65,000
| Closed | -$17.5M |
|
|
72
argenx
ARGX
$54.1B
| – | – |
-70,000
| Closed | -$34.4M |
|
73
BridgeBio Pharma
BBIO
$16.4B
| – | – |
-275,000
| Closed | -$7.25M |
|
74
Becton Dickinson
BDX
$49.4B
| – | – |
-65,000
| Closed | -$16.8M |
|
|
75
Cigna
CI
$72.4B
| – | – |
-60,000
| Closed | -$17.2M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q4 2023 Portfolio in Review
As of Q4 2023, Integral Health Asset Management held 98 positions worth $734M, up 1.7% from $722M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Integral Health Asset Management withdrew a net $87.4M in Q4 2023, closing 29 positions and reducing 20 holdings. Its most notable exit was argenx, an estimated $34.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Consumer Discretionary.
Against the trend, Integral Health Asset Management opened a new position in AbbVie worth $26.3M.
- Integral Health Asset Management's largest Q4 2023 buy was AbbVie: 170,000 shares worth $26.3M.
- Integral Health Asset Management added most to Walgreens Boots Alliance in Q4 2023, an estimated $19M increase.
- Integral Health Asset Management's biggest Q4 2023 reduction was Cytokinetics, cutting an estimated $21.7M.
- Integral Health Asset Management fully exited argenx in Q4 2023, selling an estimated $34.4M.
- Integral Health Asset Management's ten largest holdings make up 32% of its $734M portfolio in Q4 2023.
- Integral Health Asset Management opened 33 new positions and closed 29 in Q4 2023.
- Integral Health Asset Management's portfolio value rose 1.7% quarter-over-quarter to $734M.
Based on Integral Health Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.